Learning Center
Chimeric Antigen Receptor T Cell Therapy and the Outpatient Infusion Nurse [virtual]
Chimeric antigen receptor (CAR) T cell therapy is an engaging therapy that targets the CD19 or B cell maturation antigen to treat hematological malignancies. Once exclusively given in the inpatient setting, CAR T cell therapies are now transitioning to outpatient oncology infusion centers. Key components to deliver this care in the outpatient setting include multidisciplinary team involvement, comprehensive staff training, community resource engagement, creation of pathways and policies, and continuous quality assurance. In this session, we will review the science of CAR T therapy and discuss best practices for providing this treatment safely in the outpatient oncology infusion setting.
Learning Objectives: At the conclusion of this session, participants will be able to:
- Define CAR T cell therapy and the evolving strategies in the treatment of hematological malignancies.
- Describe the process of outpatient CAR T cell therapy.
- Identify best practices for long term follow-up for patients receiving CAR T cell therapy.
Contact Hours: 1
CRNI® RUs: 2
Denice Gibson, DNP, RN, CRNI®, BMTCN, AOCNS®
Dr. Denice Gibson is a clinical nurse specialist for the HonorHealth Scottsdale Shea Cancer Transplant Institute, in Scottsdale, Arizona. She has been a clinical nurse specialist for more than 30 years, supporting bone marrow transplantation, leukemia, cellular therapy, and an oncology service line. Dr. Gibson works within the 3 spheres of influence: patient care, the profession, and the community. She is active in the Oncology Nursing Society as the State Healthcare Policy Liaison and with the Arizona Nurses Association Public Policy Committee.
Key:
Complete
Next
Failed
Available
Locked